Valiant Laboratories Ltd. (IN:VALIANTLAB)
:VALIANTLAB
Want to see IN:VALIANTLAB full AI Analyst Report?
VALIANTLAB Stock Chart & Stats
₹73.50
-₹2.57(-2.33%)
At close: 4:00 PM EST
₹73.50
-₹2.57(-2.33%)
Day’s Range― - ―
52-Week Range₹47.60 - ₹114.72
Previous CloseN/A
Volume41.92K
Average Volume (3M)1.58K
Market Cap
₹3.65B
Enterprise Value₹4.60B
Total Cash (Recent Filing)₹629.06M
Total Debt (Recent Filing)₹537.68M
Price to Earnings (P/E)―
Beta0.65
Next Earnings
Aug 17, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)1.13
Shares Outstanding54,312,500
10 Day Avg. Volume2,243
30 Day Avg. Volume1,577
Financial Highlights & Ratios
PEG Ratio0.00
Price to Book (P/B)1.06
Price to Sales (P/S)1.39
P/FCF Ratio-6.98
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
API Manufacturing Business ModelValiant’s core API and bulk-drug manufacturing is a durable B2B industrial model supplying finished-dosage makers. This creates recurring, contractable demand from pharma customers and aligns the company with structural pharmaceutical production needs, supporting steady revenue potential over months.
Modest Leverage / Strong Equity BaseA sizable equity base versus low absolute debt provides financial flexibility to absorb operating volatility, fund working capital or capex, and reduces near-term solvency risk. This balance-sheet posture supports the company’s ability to weather industry cycles over a multi-month horizon.
Revenue ReboundA material revenue recovery (+29.2% YoY) and improved gross profit dollars indicate demand normalization or regained market share. If sustained, higher top-line momentum can underpin margin improvement and help restore operating leverage over several quarters.
Bears Say
Profitability DeteriorationNet income swung from prior multi-year profitability to losses and EBIT is essentially break-even. Persistent weak operating profits limit internal reinvestment, reduce the cushion for shocks, and raise the bar for management to restore sustainable margins over coming quarters.
Weak Cash GenerationOperating cash flow flipped from strongly positive in FY2023 to negative in FY2026 and free cash flow is deeply negative. Ongoing cash burn increases reliance on external funding, constrains reinvestment, and is a durable risk to operations and strategic initiatives if not reversed.
Returns On Equity And Earnings VolatilityROE volatility—strong historically then reversing to losses—signals inconsistent returns on the capital base. This undermines confidence in the firm’s ability to convert assets and equity into sustainable profits and complicates long-term capital allocation decisions.
Valiant Laboratories Ltd. News
VALIANTLAB FAQ
What was Valiant Laboratories Ltd.’s price range in the past 12 months?
Valiant Laboratories Ltd. lowest stock price was ₹47.60 and its highest was ₹114.72 in the past 12 months.
What is Valiant Laboratories Ltd.’s market cap?
Valiant Laboratories Ltd.’s market cap is ₹3.65B.
When is Valiant Laboratories Ltd.’s upcoming earnings report date?
Valiant Laboratories Ltd.’s upcoming earnings report date is Aug 17, 2026 which is in 64 days.
How were Valiant Laboratories Ltd.’s earnings last quarter?
Valiant Laboratories Ltd. released its earnings results on May 14, 2026. The company reported ₹0.32 earnings per share for the quarter, beating the consensus estimate of N/A by ₹0.32.
Is Valiant Laboratories Ltd. overvalued?
According to Wall Street analysts Valiant Laboratories Ltd.’s price is currently Overvalued.
Does Valiant Laboratories Ltd. pay dividends?
Valiant Laboratories Ltd. does not currently pay dividends.
What is Valiant Laboratories Ltd.’s EPS estimate?
Valiant Laboratories Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Valiant Laboratories Ltd. have?
Valiant Laboratories Ltd. has 54,312,500 shares outstanding.
What happened to Valiant Laboratories Ltd.’s price movement after its last earnings report?
Valiant Laboratories Ltd. reported an EPS of ₹0.32 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 3.028%.
Which hedge fund is a major shareholder of Valiant Laboratories Ltd.?
Currently, no hedge funds are holding shares in IN:VALIANTLAB
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Valiant Laboratories Ltd.
Valiant Laboratories Limited, an India-based company, specializes in the production of active pharmaceutical ingredients (APIs) and bulk drugs, serving both domestic and international markets. Its primary product is paracetamol, manufactured in various grades that meet Indian, British, European, and United States pharmacopoeia standards. This crucial compound is utilized in treatments for common ailments such as headaches, muscle aches, arthritis, backaches, toothaches, colds, and fever. Beyond pharmaceuticals, the company also supplies specialty chemicals. Originally established in 1980 and headquartered in Mumbai, India, the firm rebranded as Valiant Laboratories Limited in August 2021, having previously operated under the name Bharat Chemicals. It functions as a subsidiary of Dhanvallabh Ventures LLP.
Technical Analysis
Albert David Ltd
―
Bafna Pharmaceuticals Limited
―
Medicamen Biotech Limited
―
Medico Remedies Ltd.
―
Zim Laboratories Ltd.
―